Natera, Inc. (NASDAQ:NTRA – Get Free Report) CEO Steven Leonard Chapman sold 2,638 shares of the stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $105.16, for a total transaction of $277,412.08. Following the transaction, the chief executive officer now owns 210,377 shares in the company, valued at $22,123,245.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Steven Leonard Chapman also recently made the following trade(s):
- On Monday, July 15th, Steven Leonard Chapman sold 5,496 shares of Natera stock. The shares were sold at an average price of $111.66, for a total transaction of $613,683.36.
- On Monday, July 1st, Steven Leonard Chapman sold 37,500 shares of Natera stock. The shares were sold at an average price of $108.10, for a total transaction of $4,053,750.00.
- On Monday, June 17th, Steven Leonard Chapman sold 6,105 shares of Natera stock. The stock was sold at an average price of $111.61, for a total transaction of $681,379.05.
- On Wednesday, May 15th, Steven Leonard Chapman sold 6,779 shares of Natera stock. The stock was sold at an average price of $107.08, for a total transaction of $725,895.32.
- On Monday, April 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The stock was sold at an average price of $93.14, for a total transaction of $380,383.76.
Natera Stock Up 1.0 %
Natera stock traded up $1.01 on Tuesday, hitting $106.52. 895,366 shares of the stock traded hands, compared to its average volume of 1,329,804. The company has a current ratio of 4.12, a quick ratio of 3.98 and a debt-to-equity ratio of 0.36. The firm has a market cap of $13.08 billion, a P/E ratio of -34.14 and a beta of 1.48. The business’s fifty day simple moving average is $109.29 and its 200 day simple moving average is $91.89. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $117.23.
Hedge Funds Weigh In On Natera
Several large investors have recently modified their holdings of NTRA. Quent Capital LLC increased its holdings in Natera by 3.2% in the 1st quarter. Quent Capital LLC now owns 3,205 shares of the medical research company’s stock worth $293,000 after buying an additional 99 shares in the last quarter. GAMMA Investing LLC increased its holdings in Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after buying an additional 108 shares in the last quarter. Arcadia Investment Management Corp MI increased its holdings in Natera by 47.8% in the 1st quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock worth $49,000 after buying an additional 174 shares in the last quarter. Fifth Third Bancorp increased its holdings in Natera by 3.0% in the 4th quarter. Fifth Third Bancorp now owns 6,216 shares of the medical research company’s stock worth $389,000 after buying an additional 179 shares in the last quarter. Finally, Oliver Lagore Vanvalin Investment Group increased its holdings in Natera by 109.3% in the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after buying an additional 389 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.
Analysts Set New Price Targets
Several brokerages have recently issued reports on NTRA. Piper Sandler raised their target price on shares of Natera from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Tuesday, May 14th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a report on Friday, May 17th. TD Cowen raised their target price on shares of Natera from $123.00 to $137.00 and gave the stock a “buy” rating in a report on Friday, May 10th. Jefferies Financial Group began coverage on shares of Natera in a report on Monday, June 3rd. They issued a “buy” rating and a $142.00 target price on the stock. Finally, BTIG Research lifted their price target on shares of Natera from $100.00 to $125.00 and gave the company a “buy” rating in a report on Monday, May 13th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $101.19.
Check Out Our Latest Report on Natera
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Stories
- Five stocks we like better than Natera
- What is the NASDAQ Stock Exchange?
- ScottsMiracle-Gro Stock Blooms After Investor Day Optimism
- What is the Dow Jones Industrial Average (DJIA)?
- Leading Beverage Company’s Stock Bubbles Higher: Rally Ahead
- ETF Screener: Uses and Step-by-Step Guide
- Can This Meme Stock Stage One Last Rally?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.